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phenotypes
Aim: To know if there are phenotype differences between familial and sporadic IBD, evaluating
the prospective Spanish registry (ENEIDA) with 11,983 cases.
Methods: 5783 patients (48.3%) had ulcerative colitis (UC) and 6200 (51.7%) Crohn's disease
(CD). Cases with one or more 1st, 2nd or 3rd degree relatives affected by UC/CD were defined as
familial case.
Results: In UC and CD, familial cases compared with sporadic cases had an earlier disease onset
(UC: 33 years [IQR 25–44] vs 37 years [IQR 27–49]; p b 0.0001); (CD: 27 years [IQR 21–35] vs
29 years [IQR 22–40]; p b 0.0001), higher prevalence of extraintestinal immune-related
manifestations (EIMs) (UC: 17.2% vs 14%; p = 0.04); (CD: 30.1% vs 23.6%; p b 0.0001). Familial
CD had higher percentage of ileocolic location (42.7% vs 51.8%; p = 0.0001), penetrating
behavior (21% vs 17.6%; p = 0.01) and perianal disease (32% vs 27.1%; p = 0.003). Differences are
not influenced by degree of consanguinity.
Conclusion: When a sufficiently powered cohort is evaluated, familial aggregation in IBD is
associated to an earlier disease onset, more EIMs and more severe phenotype in CD. This feature
should be taken into account at establishing predictors of disease course.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.D
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 1. Introduction
Familial aggregation in inflammatory bowel disease (IBD) has
been documented in numerous studies.1–4 A positive family
history of IBD increases the risk of developing Crohn's disease
(CD) and ulcerative colitis (UC). The greatest risk is in
first-degree relatives, especially in siblings and it is higher in
patients with CD than in those with UC. The rate of family
history in CD ranges from 2% to 14%, and in UC from 7% to
11%.2,5,6 The role of genetic factors in IBD has been shown by
epidemiological, familial and genome-wide association (GWA)
studies. Previous analyses on the phenotypic differences
between familial and sporadic IBD are controversial. Whereas
some studies did not show phenotypic differences,4,7,8 others
found that in familial cases, disease onset occurs at an earlier
age and suffers from a higher disease extent than in sporadic
cases.9,10 Provision of robust data on this aspect might prove
of value in our goal to offer our patients a personalized health
care.
As familial aggregation only occurs in a minority of
patients with IBD, the main limitation of the published
reports addressing this aspect is the limited power to
evidence relevant differences in phenotype between spo-
radic and familial cases. To overcome these limitations we
took advantage of the prospective Spanish registry of IBD
cases, ENEIDA (Estudio Nacional en Enfermedad Inflamatoria
intestinal sobre Determinantes genéticos y Ambientales),
that included 11,983 patients at the time this study was
undertaken. This represents a sample size 10-fold higher
than the largest study published so far.1.1. Patients and methods
The study included 11,983 IBD patients (48.3% UC and 51.7%
CD) registered in the ENEIDA database, a Spanish database
that collects prospective data of incident and prevalent
cases of IBD treated at 35 Spanish hospitals since January
2006. Patients diagnosed with other types of IBD (unclassi-
fied or, indeterminate IBD or microscopic colitis) were
excluded. Events occurring before inclusion of the patientin the database were acquired retrospectively from local
database or case records.
1.2. Description of variables
The variables captured included: demographic data, clinical
phenotype including IBD type, age at diagnosis, gender,
smoking habits before and after diagnosis, family history of
IBD including number of affected relatives and degree of
kinship, disease location and extent, disease behavior (for CD)
according to the Montreal classification,11 extraintestinal
immune-related manifestations (EIMs) of IBD and surgical
requirements during follow-up.
1.3. Definitions established in the database are the
following
The database prospectively established the following defi-
nitions: Smokers were defined as patients who smoked more
than 7 cigarettes per week. Ex-smokers were defined as
patients who had given up smoking for at least 1 year.
Nonsmokers were defined as patients who had never smoked
more than 7 cigarettes per week.12
1.3.1. Disease location and disease behavior
Disease location and disease behavior were determined
according to at least one imaging technique (endoscopy,
small bowel follow through, or a cross-sectional imaging
technique). The maximal extent of involvement and the
most severe form of disease behavior at any time since
diagnosis were recorded. Disease phenotype was catego-
rized according to the Montreal classification.11
The EIMs of IBD were defined as reactive manifesta-
tions including: arthritis, erythema nodosum, pyoderma
gangrenosum, aphthous stomatitis, iritis/uveitis and autoim-
mune diseases such as primary sclerosing cholangitis.
1.3.2. Familial IBD
Familial IBD was defined as the existence of one or more
first, second and/or third degree relatives affected with
Table 1 Demographic data in ulcerative colitis (UC) and
Crohn's disease (CD).
Total cases UC patients CD patients p value
5783 6200
Follow-up (months) 91 (38–166) 92 (39–164) 0.03
Median (IQR) a
Age at diagnosis (years) 36 (27–49) 29 (22–39) 0.0001
Median (IQR) a
Female gender (%) 46.8 53.2 0.002
Smoking at diagnosis (%) 16.8 44.8 0.0001
EIMs (%) b 14.3 24.5 0.0001
Familial cases (%) 10.2 14 0.0001
a Interquartile range.
b Extraintestinal manifestations.
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 either CD or UC. The number of relatives with any IBD was
registered. Patients without any relative affected with IBD
were categorized as sporadic IBD. An effort was made to
verify reported IBD in relatives by obtaining medical records
whenever possible. All these terms were prospectively
defined and categorized by the investigators in each center.
The database is kept under continuous external monitor-
ing for completeness and consistency of the data entered,
but data can only be modified by each local investigator.
The study was approved by the institutional ethics
committee of each participating hospital and written
informed consent was obtained from all patients.
2. Statistical analysis
Continuous data were compared using Student's t test and
were expressed as median and interquartile range (IQR).
Categorical data were analyzed by Chi square test.
Probability curves for surgery need in sporadic and
familial IBD were calculated according to the Kaplan–Meier
method and were compared using the log-rank test.
Linear regression was performed to assess whether
familial history of IBD was an independent predictor for
younger age at diagnosis in UC and CD (dependent variable).
Gender, smoking at diagnosis and family history of IBD were
included as independent variables. Results are reported as
odds ratios (OR) with 95% confidence intervals (95% CI). All
p values were two-sided. A p value of less than 0.05 was
considered statistically significant difference. p values of
t-tests or X2 tests have not been corrected for multiple
comparisons. Analyses were performed with SPSS V19.0
software package (SPSS Inc., Chicago, IL).
3. Results
3.1. Study population
The study cohort included 11,983 patients with an established
diagnosis of UC or CD (48.2% females, and 51.8% males);
median age at diagnosis, 32 years (IQR 24–44). There were
5783 (48.3%) patients diagnosed with UC and 6200 (51.7%)
patients with CD. According to family history, 10,523 patients
(87.8%) had sporadic IBD, and 1460 patients (12.2%) had
familial IBD. In Table 1 the demographic characteristics of
patients with UC and CD are summarized.
3.2. Familial and sporadic ulcerative colitis
There were 5194 patients with sporadic UC (89.8%), and 589
cases with familial UC (10.2%); among the later group 65%
had one or more first degree relatives affected by IBD and
35% had only second or third degree relatives affected. As
shown in Table 2 median age at diagnosis was significantly
lower in the familial group compared to the sporadic group
(33 years (IQR 24–44) vs 37 years (IQR27–49); p b 0.0001),
but no differences were observed in other demographic or
environmental risk factors such as gender, smoking habit or
previous appendectomy. Although disease extent was similar
in both groups, there was a higher proportion of patients
with EIMs in the familial group (17.2%) than in the sporadicgroup (14%) (p = 0.04). The analysis of survival time free of
surgery through Kaplan–Meier analysis did not show signif-
icant differences between groups (p = 0.1).
Duration of follow-up was similar in sporadic and familial
cases. No differences were found between the group of
patients with familial UC who had first degree relatives
affected and the group of patients with only second or third
degree relatives in terms of demographic and clinical
characteristics.3.3. Familial and sporadic Crohn's disease
A total of 6200 patients with CD were included in the study.
In the sporadic group there were 5329 cases (86%), and the
familial group comprised 871 cases (14%); 60.19% of them
had at least one or more first degree relatives affected by
IBD and 39.8% had only second and/or third degree relatives
affected by IBD as shown in Table 4. No differences were
found between the group of patients with familial CD who
had first degree relatives affected and the group with only
second or third degree relatives in terms of demographic and
clinical characteristics. The median age at diagnosis was
significantly lower in the familial group compared to the
sporadic group (27 years (IQR 21–37) vs 29 years (IQR22–40);
p b 0.0001) and there was a higher proportion of patients
with EIMs among the familial cases (30.1%) than in the
sporadic cases (23.6%) (p b 0.0001). Disease location was
different in the two groups of patients. Compared to the
sporadic group, familial cases had a significantly higher
proportion of cases with ileocolonic location (42.7% vs
51.7%; p b 0.0001). The evaluation of disease behavior at
the time of diagnosis demonstrated that the penetrating
phenotype was significantly more frequent in the familial
group than in the sporadic group (21% vs 17.6%; p = 0.01).
Perianal disease was also more frequent at disease onset in
the familial group (32% vs 27.1%; p = 0.003) (Table 4).
However, the Kaplan–Meier analysis did not show significant
differences in the survival time free of surgical treatment
among the two groups (p = 0.3). The median duration of
follow-up was significantly higher in the familial group
compared to the sporadic group (106 months [IQR 45–179] vs
90 months [IQR 38–162]; p b 0.0001).
Table 2 Characteristics of UC, according to sporadic disease and familial aggregation (statistically significant results are
highlighted in bold).
A
Sporadic IBD
B
Familial IBD
C
1st degree
relatives affected
D
2nd, 3rd degree
relatives affected
p value
Total patient N = 5194 N = 589 N = 354 N = 182 A vs B A vs C A vs D
Follow-up median (IQR) a 89 (37–165) 100 (44–178) 107 (48–191) 100 (40–174) 0.09 0.007 0.7
Age at diagnosis median (IQR) a 37 (27–49) 33 (24–44) 33 (25–44) 30 (23–42) 0.0001 0.0001 0.0001
Gender/female (%) 46.5 47.2 47.2 47.3 0.7 0.8 0.8
Smokers at diagnosis (%) 16.7 17.6 17.3 17.3 0.5 0.7 0.2
Appendectomy (%) 4.1 3.8 3.9 4 0.7 1 1
EIMs (%) b 14 17.2 17.1 15.8 0.04 0.04 0.5
Location (%)
Montreal E1 17.4 18.1 17 20.3 0.6 0.9 0.3
Montreal E2 43.3 39.5 41.5 35.6 0.09 0.5 0.04
Montreal E3 39.3 42.3 41.5 44.1 0.1 0.4 0.2
a Interquartile range.
b Extraintestinal manifestations.
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 The results of regression analysis are shown in Table 3.
The familial aggregation independently reduces the age at
diagnosis by 4.16 years (95% CI 2.82–5.51) in UC and by
3.46 years (95% CI 2.41–4.51) in CD. by guest on N
ovem
ber 16
/ecco-jcc.oxfordjournals.org/4. Discussion
The current study analyzed a large IBD registry comparing the
disease phenotype at diagnosis and during follow-up in
patients with CD and UC according to existence of familial
aggregation. For both diseases familial cases have an earlier
disease onset, and a higher prevalence of EIMs. The analysis
showed that at the disease onset familial CD is more severe
with a higher percentage of penetrating behavior and perianal
disease than sporadic disease, and is associated with a higher
prevalence of ileocolic disease location. Despite the higher
prevalence of penetrating behavior and perianal disease in
familial CD cases at the time of diagnosis, surgery require-
ments did not differ between the two groups, which may beTable 3 Independent predictors of age at diagnosis in
ulcerative colitis and Crohn's disease.
Ulcerative colitis Crohn's disease
N = 5783 N = 6200
Dependent
variables
Coefficient β
(95% CI)
p value
Coefficient β
(95% CI)
p value
Female gender −3.09
(−3.90 to −2.27)
b0.0001
1.00
(−2.24–3.75)
0.9
Smoking at
diagnosis
−3.55
(4.64 to −2.47)
b0.0001
−3.42
(−4.15 to −2.70)
b0.0001
Familial
aggregation
−4.16
(−5.51 to −2.82)
b0.0001
−3.46
(−4.51 to −2.41)
b0.0001
, 2015related to initiation of early medical interventions resulting in
decreased surgical needs. Differences between sporadic and
familial cases were not influenced by the number of relatives
affected or the degree of consanguinity (first vs second or
third degree relatives).
The strength of this study relies on several facts. First,
the large number of cases included in the study makes the
results robust. Second, ENEIDA registry standardized data
capture on phenotype characteristics of UC and CD (Montre-
al definition) as well as definitions of smoking and EIMs. This
has the advantage of setting a benchmark for data capture
and increasing the accuracy of the information obtained.
Third, all data collected since January 2006 were prospec-
tive, and the information of the patients enrolled in the
registry has been updated after each outpatient visit or
hospital events, so the data of the disease follow-up are
mostly prospective. Fourth, data are subject to external
monitoring for completeness and consistency. Finally, we
could directly verify familial IBD in 40% of relatives because
they were also included in the ENEIDA registry. The
coincidences of demographic data of the population includ-
ed with that of prospective population base studies,13,14 also
confirm the reliability of data captured in ENEIDA database.
The study has limitations that should not be ignored.
First, this is not a true population based study. ENEIDA
registry covers IBD hospital population, collecting informa-
tion of cases that require either outpatient control or
hospital admission, this could justify that the distribution
of cases with UC and CD around 1:1 in our cohort differs from
that observed in population-based studies, where the
prevalence of UC cases is higher than CD by a 5:3 ratio.15
The population of patients included in the current study
could also contain an overrepresentation of IBD patients
with positive family history or with a more severe disease
course compared to true population-based studies. Never-
theless due to the open access of patients to referral
centers, and the advocacy of patient groups, care of IBD
patients in Spain (severe and non-severe) is highly con-
centrated in the hospital setting. In our study cases with
familial IBD had a higher proportion of EIMs. Previous reports
on the prevalence of EIMs in sporadic and familial IBD are
Table 4 Characteristics of Crohn's disease, according to sporadic disease and familial aggregation disease (statistically
significant results are highlighted in bold).
A
Sporadic IBD
B
Familial IBD
C
1st degree
relatives affected
D
2nd, 3rd degree
relatives affected
p value
Total patient N = 6.200 N = 871 N = 520 N = 261 A vs B A vs C A vs D
Follow-up (months) median (IQR) a 90 (38–162) 106 (45–179) 115 (47–189) 99 (39–158) 0.0001 0.0001 0.3
Age at diagnosis median (IQR) a 29 (22–40) 27 (21–35) 28 (21–37) 25 (21–31) 0.0001 0.001 0.0001
Gender/female (%) 47.5 52.5 53.5 51.2 0.057 0.04 0.4
Smokers at diagnosis (%) 49.8 53.5 53.5 54 0.06 0.1 0.1
EIMs (%) b 23.6 30.1 28.8 32.3 0.0001 0.01 0.001
Location (%)
Montreal L1 38.9 37.4 37.1 38.2 0.4 0.4 0.8
Montreal L2 14.1 11.4 11.5 10 0.03 0.07 0.03
Montreal L3 42.7 51.7 51.3 51.8 0.0001 0.002 0.01
Montreal L4 15.3 15.7 15.7 13.8 0.8 0.8 0.5
Disease behavior c
B1 (%) 65.5 67.4 67.7 67.2 0.2 0.3 0.5
B2 (%) 25 25.6 26.2 23.9 0.7 0.5 0.7
B3 (%) 17.6 21 20.3 22.5 0.01 0.1 0.03
Perianal (%) 27.1 32 31.3 33.1 0.003 0.04 0.02
a Interquartile range.
b Extraintestinal manifestations.
c Disease behavior categorized according to the Montreal classification.
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 controversial. Some studies have demonstrated a higher
prevalence of EIMs in the familial group,16,17 whereas no
difference was found in another study between familial and
sporadic IBD.18 Sensitivity analyses in subgroups of patients
with CD/UC or with 1st/2nd–3rd degree relatives provide
confirmatory evidence of this association in the current
study. The reason for higher EIMs in familial cases is not
apparent. It is known that EIMs have a familial predisposi-
tion,17 suggesting the existence of a strong genetic influence
on this phenotypic trait. Some studies suggest that genetic
load is higher in familial cases19–21 and some susceptibility
genes for IBD confer also susceptibility to other immune
mediated inflammatory disorders. One example of this is the
HLA system which is one of the major genetic markers
associated with IBD and EIMs. 22–25
Another notable aspect evaluated in this study was the
assessment of familial IBD according to the degrees of
consanguinity. Interestingly in both, familial UC and CD,
patients had the same differences in disease characteristics
when compared to sporadic cases whether they had first
degree relatives or more distant relatives. Most familial
aggregation studies included only first-degree relatives;
there is little information about other degrees of consan-
guinity and IBD characteristics. This study is the first to
report robust information about the effect of IBD aggrega-
tion when patients only have distant relatives affected.
Finally we want to emphasize the difference in severe
phenotype at disease onset between familial CD and familial
UC. There are some family data suggesting a stronger
genetic influence in CD than in UC, such as more common
family history or a higher proportion of concordance among
homozygotic twins.26–28 But genetic risk factors explain only
a fraction of the estimated heritability and there are also
strong environmental factors such as smoking that increase
the predisposition to CD.5. Conclusion
The study demonstrates that when a sufficiently powered
cohort of cases is interrogated, familial aggregation in IBD is
associated to an earlier disease onset, more severe pheno-
type, and more EIMs. This feature should be taken into
account in future studies aimed at establishing prognostic
factors, and may also have practical implications for patient
care when the predictive ability of family aggregation is
gauged relative to other predictors particularly at the time
of diagnosis, when information on disease characteristics is
considerably limited.
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